Katsuyuki Kiura

7PUBLICATIONS
44CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 29, 2025
Colony-Stimulating Factor-1 Receptor Inhibitor Augments Osimertinib-Induced Antitumor Immunity via Suppression of Macrophages in Lung Cancer Harboring EGFR Mutation.

Sachi Okawa, Shuta Tomida, Tadahiro Kuribayashi

|Apr 10, 2024
A single arm Phase I/II trial on the combination of carboplatin, nab-paclitaxel and avastin as first-line treatment for advanced non-squamous non-small cell lung cancer (TORG1424/OLCSG1402: CARNAVAL).

Naoyuki Nogami, Toshio Kubo, Akihiro Bessho

|Mar 16, 2023
Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration.

Takao Morinaga, Takashi Inozume, Masahito Kawazu

|Jul 08, 2022
CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr-Mutant Lung Cancer.

Kazuya Nishii, Kadoaki Ohashi, Shuta Tomida

|Jun 23, 2021
SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non-small Cell Lung Cancer.

Hirohisa Kano, Eiki Ichihara, Hiromi Watanabe

|Jan 25, 2018
Osimertinib in patients with epidermal growth factor receptor T790M advanced non-small cell lung cancer selected using cytology samples.

Katsuyuki Kiura, Kiyotaka Yoh, Nobuyuki Katakami

Pageof 2

Frequent Collaborators

3 joint publications

Kadoaki Ohashi

3 joint publications

Eiki Ichihara

2 joint publications

Shuta Tomida

2 joint publications

Takamasa Nakasuka